D-Pharm Ltd (DPRM: TASE) 宣布，该公司已经根据特殊试验方案评价 (Special Protocol Assessment, SPA) 程序与美国食品和药物监督管理局 (FDA) 就该公司针对急性缺血性脑中风患者而开展的神经保护剂 DP-b99 关键的三期试验 (MACSI) 达成协议。这份 SPA 同意书表明“此项研究的设计 ...

Drug-drug interactions must be considered when treating patients with antidepressants or antipsychotics. Pharmacodynamic interactions are of concern in such patients, as many antidepressants and ...